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Background: After the failure of a non-steroidal aromatase inhibitor (nsAI) for postmenopausal patients with
metastatic breast cancer (mBC), it is unclear which of various kinds of endocrine therapy is the most appropriate. A
randomized controlled trial was performed to compare the efficacy and safety of daily toremifene 120 mg
(TOR120), a selective estrogen receptor modulator, and exemestane 25 mg (EXE), a steroidal aromatase inhibitor.
The primary end point was the clinical benefit rate (CBR). The secondary end points were objective response rate
(ORR), progression-free survival (PFS), overall survival (OS) and toxicity.
Methods: Initially, a total of 91 women was registered in the study and randomly assigned to either TOR120
(n = 46) or EXE (n = 45) from October 2008 to November 2011. Three of the 46 patients in the TOR120 arm were
not received treatment, 2 patients having withdrawn from the trial by their preference and one having been
dropped due to administration of another SERM.
Results: When analyzed after a median observation period of 16.9 months, the intention-to-treat analysis showed
that there were no statistical difference between TOR120 (N = 46) and EXE (n = 45) in terms of CBR (41.3% vs. 26.7%;
P = 0.14), ORR (10.8% vs. 2.2%; P = 0.083), and OS (Hazard ratio, 0.60; P = 0.22). The PFS of TOR120 was longer than
that of EXE, the difference being statistically significant (Hazard ratio, 0.61, P = 0.045). The results in treatment-
received cohort (N = 88) were similar to those in ITT cohort. Both treatments were well-tolerated with no severe
adverse events, although the treatment of 3 of 43 women administered TOR120 was stopped after a few days
because of nausea, general fatigue, hot flush and night sweating.
Conclusions: TOR120, as a subsequent endocrine therapy for mBC patients who failed non-steroidal AI treatment,
could potentially be more beneficial than EXE.
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The goal of treatment for metastatic breast cancer
(mBC) is to maintain the quality of life (QOL) and pro-
long survival of patients. When patients have non-life-
threatening metastases that are suspected to be hormone
sensitive (i.e., in breast cancer that is estrogen receptor
[ER]- or progesterone receptor [PgR]-positive), it is desir-
able to continue endocrine therapy as long as possible,
since the therapy itself has a minimal negative effect on
the QOL [1]. Non-steroidal aromatase inhibitors (nsAIs),
such as anastrozole and letrozole, have been mainly
employed as early recurrent treatment for postmeno-
pausal breast cancer [2,3]. When nsAI treatment fails, it is
unclear which endocrine therapy is the most appropriate.
Options include selective estrogen receptor modulators
(SERMs), fulvestrant, a selective ER down regulator
(SERD), and exemestane.
Exemestane (EXE) is a steroidal AI (sAI) with modest
androgenic activity, which was studied in a phase II trial
after documented progression during treatment with an
nsAI, and showed a clinical benefit rate (CBR) of 20-40%
[4]. Toremifene (TOR) is a SERM with a reported effi-
cacy for treatment of postmenopausal breast cancer
similar to that of tamoxifen (TAM) [5]. The usual dose
of TOR is 40 mg given orally once a day, however, high-
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Figure 1 A consort diagram of this trial. A total of 91 women was rand
analyzed as intention-to-treat (ITT) cohort. Three of the 46 patients in the T
the trial by their preference and one having been dropped due to adminis
were analyzed the efficacy and safety as ‘treatment-received’ cohort. Three
TOR120 early because of adverse effects.for use in Japan. High-dose TOR has been reported to
compete with estrogen at the ligand-binding site of the
ER, to suppress insulin-like growth factor-1-dependent
growth [6] and to have non-ER-dependent anti-tumor ef-
fects such as suppression of angiogenesis [7]. In our previ-
ous retrospective study (Hi-FAIR study), TOR120 showed
a CBR of 45% and ORR of 10% after prior AI [8].
In the present study, we conducted an open labeled,
randomized controlled trial for patients with postmeno-
pausal mBC that had progressed following the adminis-
tration of an nsAI. The effectiveness and safety of
TOR120 were compared to EXE.
Methods
Study design
The high-dose toremifene (Fareston®) for patients with
non-steroidal aromatase inhibitor-resistant tumor com-
pared to exemestane (Hi-FAIR ex) study group consists of
experts in breast cancer endocrine therapy from 15 facil-
ities (registry number UMIN000001841). This is a random-
ized, open labeled trial designed to compare the efficacy
and tolerability of toremifene 120 mg to exemestane in
postmenopausal women with hormone receptor positive
mBC with disease progression after prior nsAI treatment.
Study treatment continued until disease progression, in-
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omly assigned to either TOR120 (n = 46) or EXE (n = 45), who were
OR120 were not received treatment, 2 patients having withdrawn from
tration of another SERM. Except for these 3 cases, 43 cases of TOR120
of 43 treatment-received patients with TOR120 were dropped out of
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she is switched to the other arm if possible. This data will
be analyzed after 12 more months’ follow-up.
The primary end point of the study was clinical benefit
rate (CBR). Secondary end points included objective
response rate (ORR), progression free survival (PFS),
overall survival (OS), and tolerability. The trial was
designed to detect superiority of TOR120 compared
with EXE in terms of CBR. In the literature, the CBR ofTable 1 Patient and tumor characteristics at baseline
Characteristics
Number of the patients
Age; median (range)
Follow-up period (weeks); median (range)
Time elapsed after menopause (years); median (range)
Body Mass Index; median (range)
DFI in recurrent cases (months); median (range)
Estrogen Receptor status Positive
Negative
Unknown












Performance status (cases) 0,1
2




Previous aromatase inhibitor (%) Anastrozole
Letrozole
Previous treatment with tamoxifen (%)
Previous chemotherapy (%)
Sensitivity to previous aromatase inhibitor treatment;
Clinical Benefit Rate (%)
Duration of previous aromatase inhibitor(months); median (range)TOR120 could be considered about 45% and that of
EXE as 30% [8-10]. To prove a probability of 90% that
TOR120 was superior 15% superior to EXE, 41 patients
were required for each group. To account for dropouts
and protocol violations, we planned to recruit 90 pa-
tients (45 in each treatment group). Additionally, this
trial is thought to be not actually a Phase II trial, but a
rather small Phase III trial designed to show a big differ-
ence between the 2 groups.TOR120 EXE
46 45
63 (51–87) 62 (49–87)
69 (13–144) 81 (13–160)
13 (2–37) 13 (1–37)
22.9 (18.0-35.2) 23.4 (27.7-35.4)

























17/23 (74%) 20/30 (67%)
17.1 (2.0-80.8) 17.6 (2.4-65.3)
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after the last case was enrolled in the trial. The crossover
data would be analyzed at one year after the first analysis.
Patients
Key inclusion criteria of this study were as follows; the
patients are postmenopausal women (over 60 years old,
or over 45 years old with amenorrhea over 1 year and
follicle stimulating hormone levels within the postmeno-
pausal range), with breast cancer confirmed by patho-
logical diagnosis, who had progressive disease during or
after prior non-steroidal AI, who have at least one meas-
urable site or evaluable bone metastasis, who have ER
positive and/or PgR positive tumors in the primary or
metastatic site, who have anticipated survival of more
than 6 months and WHO performance status (PS) 1 or
PS2 due only to bone metastasis. This study included
patients with bone only (lytic or mixed) metastatic dis-
ease by assessing variation of serum tumor markers and
bone imaging, or, if possible, measuring the bone lesions
with CT or MRI. Up to one prior chemotherapy regimen
for the treatment of advanced/recurrent BC was allowed.
Use of tamoxifen for adjuvant treatment and for ad-
vanced breast cancer was also allowed.
Exclusion criteria included the presence of other active
malignancies, pregnancy or lactation, life-threatening
metastatic visceral disease, brain or leptomeningeal
metastasis, prior exposure to either TOR120 or EXE, ex-
tensive radiation or cytotoxic therapy within the last
4 weeks or being judged inappropriate by physicians. All
women provided written informed consent before
registration in the trial. The study was conducted in ac-




Long stable disease (≥ 24 weeks) 14
Stable disease (< 24 weeks) 9
Progressive disease 12
* Withdrew prior to therapy 3*
** Drop out due to early adverse events (not evaluable) 3**
Intention-to-treat cohort N = 46
Clinical benefit rate% (95% CI) 41.3 (2
Response rate% (95% CI) 10.8 (4
Treatment-received cohort N = 43
Clinical benefit rate% (95% CI) 44.2 (3
Response rate% (95% CI) 11.6 (5
*Three patients of all 46 cases withdrew the protocol because of their preference o
assessed as ‘Treatment-received cohort’. **Three other patients dropped out of tore
CI; confidence interval, ITT; intention-to-treat.Declaration of Helsinki and with local Institutional Re-
view Board approval at each participating center.
The ER, PgR, and human epidermal growth factor re-
ceptor 2 (HER2) status of each patient was analyzed at
each participating facility, if possible. Generally, ER and
PgR were measured by immunohistochemistry (IHC),
and positive and negative status was judged on the basis
of the standard criteria used at each facility, typically
with a cut-off level of 1%. HER2 was assayed by IHC
and/or FISH and in accordance with ASCO-CAP.
Endpoints and methods of evaluation
The tumor reduction effect was evaluated every 8 weeks
based on Response Evaluation Criteria in Solid Tumors
(RECIST) [11]. A complete response (CR) was defined
as the complete disappearance of the measurable lesions;
a partial response (PR) as a decrease by 30% or more in
the sum of the longest diameters (LDs) of measurable le-
sions; progressive disease (PD) as an increase of 20% or
more in the sum of the LDs of measurable lesions; and
long lasting stable disease (long SD) as no change in the
size of measurable lesions for 24 weeks or longer. The
objective response rate (ORR) was defined as the sum of
the frequencies of CR and PR and the clinical benefit rate
(CBR) as the sum of the frequencies of CR, PR and long
SD. Patients with only bone metastasis were included in
the progression analysis by measuring changes in serum
tumor markers, such as CEA, CA15-3. Specifically, reduc-
tion in tumor markers and complete calcification, with
improvement of bone symptoms were judged to be PR.
Adverse events were evaluated using the National
Cancer Institute Common Toxicity Criteria, Version 4.
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Hazard ratio, 0.61 (95% CI, 0.38-0.99)
P=0.045 by log-rank test
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Figure 2 Kaplan-Meier progression-free survival and overall survival curves. a. The median progression free survival (PFS) in toremifene
120 mg/day (TOR120) was 7.3 months and that in exemestane 25 mg/day (EXE) was 3.7 months, which showed a statistically significant
difference with a hazard ratio of 0.61 (95% Confidence Interval; 0.38-0.99, P = 0.045). b. Kaplan-Meier overall survival (OS) curves in the TOR120
and EXE. The median OS in TOR120 was 32.3 months and that in EXE was 21.9 months, which showed no statistical difference with a hazard ratio
of 0.60 (95% CI; 0.26-1.39, P = 0.22) by log-rank test.
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independently reviewed and judged by the clinical trial
office, Kumamoto University.
Statistical analysis
SAS was used for statistical analyses of the correlation
between therapeutic effects and clinicopathological
factors. Unpaired groups were compared using an un-
paired t-test and paired groups were compared using
Fisher’s exact test. PFS and OS were analyzed using theKaplan-Meier method and the results were compared by
log-rank test.
Results
Baseline characteristics and medical history of patients
Initially, a total of 91 women was registered in this study
and randomly assigned to either TOR120 (n = 46) or
EXE (n = 45) from October 2008 to November 2011
(Figure 1). These patients were analyzed as intention-
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Figure 3 Subgroup analyses of consistent results for clinical
benefit; There were no statistical significant differences.
Table 3 Adverse Events of toremifene 120 mg and
exemestane 25 mg in 88 treated patients
TOR120 (n = 43) EXE (n = 45)
Grade1,2 Grade3,4 Grade1,2 Grade3,4
Nausea 4* 0 1 0
Fatigue 3* 0 1 0
Hot flush 3* - 1 -
Night sweating 3* - 0 -
Vaginal bleeding,
discharge
2 - 0 -
Joint pain, disorder 1 - 2 -
Liver dysfunction 1 0 1 0
Exanthema 1 0 0 0
* Three of 43 women treated with toremifene 120 mg were withdrawn from
the trial in a few days because of early nausea, fatigue, hot flush and night
sweating, which were appeared in same 3 patients.
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drawn from the trial by their preference and one having
been dropped due to administration of another SERM.
Except for these 3 patients, forty-three patients with
TOR120 were analyzed the efficacy and safety as the
treatment-received patients (n = 88) (Figure 1).
There was no difference between TOR120 (N = 46)
and EXE (N = 45) arm in the patients’ characteristics as
listed in Table 1. The median age was 62.2 years (range,
49 to 87) and the median observation period was 72 weeks
(range 13–160). Almost of all patients had ER-positive
(96%) and HER2-negative (91%) tumors. At the start of
the treatment, 20 of the TOR120 arm (44%) and 19 of
EXE arm (42%) had visceral metastases, such as metastasis
to the lung, liver, or pleura. However, the EXE arm had a
slightly greater number of women with bone metastasis
(31%, 14/45) than the TOR120 arm (20% 9/46). CBR of
the TOR120 arm during treatment with the prior nsAI for
ABC was 74% (17/23), and that of EXE arm was 67% (20/
30), which was not statistically significant. Approximately
40% of the patients had received chemotherapy for MBCbefore this trial. Trastuzumab was not used either before
or during the trial.
Efficacy
Intention-to-treat analysis at a median observation
period of 16.9 months showed that there was no statis-
tical significant difference between TOR120 (N = 46) and
EXE (N = 45) in terms of CBR (41.3% vs. 26.7%; P = 0.14)
and ORR (10.8% vs. 2.2%; P = 0.083) (Table 2). The me-
dian PFS in TOR120 was 7.3 months and that in EXE
was 3.7 months, which showed a statistically significant
difference with a hazard ratio of 0.61 (95% Confidence
Interval, 0.38-0.99), P = 0.045 (Figure 2a). The median
OS in TOR120 was 32.3 months and that in EXE was
21.9 months, which showed no statistical difference with
a hazard ratio of 0.60 (95% CI; 0.26-1.39), P = 0.22
(Figure 2b).
In the treatment-received samples, there was neither
between TOR120 (N = 43) and EXE (N = 45) in terms of
CBR (44.2% vs. 26.7%; P = 0.085) nor ORR (11.6% vs.2.2;
P = 0.069) (Table 2). Duration of response has not yet
been analyzed, because twelve patients (27.9%) of the
TOR120 arm and 6 patients (13.3%) of the EXE arm
were still being treated at the median observation period
of 72 weeks.
Subgroup analysis
In an investigation of the consistency of treatment effect
across the predefined covariates, there were no statisti-
cally significant differences. For examples, there was no
correlation between the superiority of TOR120 and
patients’ age, time since menopause, body mass index,
baseline performance status, response to previous AI,
presence or absence of viscera metastasis, number of
previous hormonal therapies, previous tamoxifen treat-
ment, previous chemotherapy or PgR status (Figure 3).
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Three of 43 women treated by TOR120 withdrew after a
few days because of nausea, fatigue, hot flush, and night
sweating, which were thought to be endocrine-related
symptoms. Except for these 3 cases, both treatments
were well tolerated with no severe adverse events
(Table 3).
Discussion
In our report, a randomized controlled trial was per-
formed to compare the efficacy and safety of daily
toremifene 120 mg (TOR120; N = 46) and exemestane
25 mg (EXE; N = 45). Although there were no statistical
difference between TOR120 and EXE in terms of CBR
(P = 0.14), ORR (P = 0.083) and OS (P = 0.22), the PFS of
TOR120 was longer than that of EXE (P = 0.045). These
results suggested that TOR120, as a subsequent endo-
crine therapy for mBC who failed non-steroidal AI treat-
ment, could potentially be more beneficial than steroidal
AI. Both treatments were well-tolerated with no severe
adverse events.
Various endocrine therapies are indicated for postop-
erative adjuvant therapy of hormone-dependent and re-
current breast cancer [2]. Particularly indicated in cases
of postmenopausal breast cancer are treatments that
modulate ER function using SERMs and SERDs as well
as powerful and highly selective treatments that suppress
estrogen synthesis using third-generation AIs. AIs are
considered the agent of first choice for endocrine ther-
apy in TAM-failure cases. Especially, nsAIs have been
primarily used in postoperative adjuvant therapy or as
first line treatment for recurrence. The question arises
as to the best choice of subsequent endocrine agent for
cases that are refractory to AI.Table 4 The efficacy of subsequent endocrine therapy for adv
non–steroidal aromatase inhibitor
Author; Journal, year (Trial name) Line D
Lϕnning; J Clin Oncol, 2000 [9] 2nd ~ 4th ns
Iaffaioli; Br J Cancer, 2005 [10] 2nd ~ 3rd AN
Steele; Breast, 2005 [4] 2nd~ > 4th ns
Thürlimann; Eur J Cancer, 2003 [13] 2nd AN
Chia; J Clin Oncol, 2008 (EFECT) [12] 2nd~ > 4th ns
ns
Yamamoto; Breast Cancer, 2010 (Hi-FAIR) [8] 2nd~ > 4th AI
Di Leo; J Clin Oncol, 2010 [14] 2nd AI
AI
Bachelot T: J Clin Oncol. 2012 (TAMRAD) [17] 2nd~ > 4th ns
ns
Baselga; N Engl J Med, 2012 (Bolero2) [16] 2nd ~ 4th ns
ns
nsAI: non-steroidal aromatase inhibitor, EXE: exemestane, ANA: anastrozle, TAM: tamOne option is another AI, such as EXE, which has a
steroidal structure and different mechanism of suppress-
ing aromatase activity. Lϕnning et al. [9] reported that
the ORR and CBR of EXE after nsAI failure (n = 105)
were 4.8% and 20.0%, respectively. In other reports, the
CBR of EXE after nsAI failure was around 45% in the
second or third line endocrine therapy [1,10]. Chia et al.
[12] reported that the ORR and CBR of EXE after nsAI
failure (n = 270) as a control arm in their trial were 7.4%
and 32.2%, respectively (Table 4).
SERMs provide a second option: their various ligand-
dependent effects are enhanced by the lower estrogen
concentrations in breast cancer tissues that follow treat-
ment with AIs. The ORR and CBR of TAM treatment
after nsAI failure (N = 95) were 7.4% (7 cases) and 56.8%
(54 cases), respectively [13]. We previously analyzed the
efficacy of TOR120 in 80 AI-failure cases: the ORR and
CBR were 15% and 45%, respectively, and the median
TTF was 7.8 months, which demonstrated satisfactory
efficacy outcomes, although this study was retrospective
[8] (Table 4). High-dose TOR was reported to compete
with estrogen at the site of the ER, to suppress insulin-
like growth factor-I-dependent growth [6] and to have
non-ER-dependent anti-tumor effects such as suppres-
sion of angiogenesis [7].
A third option is the use of much stronger endocrine
therapy, such as SERDs, especially high-dose fulvestrant
(500 mg on the first day, day 14, and day 28, followed by
500 mg/4 weeks thereafter), which produced a signifi-
cant increase in PFS compared with the conventional
250 mg regimen [14]. Unfortunately, high-dose fulvestrant
was not approved in Japan until the end of 2011, so we
could not include it in the present study. Our group of in-
vestigators is conducting another comparative study ofanced breast cancer who have failed to respond to
esign n ORR (%) CBR (%)
AI→ EXE 105 4.8 20.0
A→ EXE 50 8.0 44.0
AI→ EXE 114 5.0 46.0
A→ TAM 119 10.1 48.7
AI→ FUL loading dose 270 7.4 32.2
AI→ EXE 270 6.7 31.5
s→ TOR120 80 15.0 45.0
or SERM→ FUL500 362 9.1 45.6
or SERM→ FUL250 374 10.2 39.6
AI→ TAM 57 13.0 42.1
AI→ TAM + RAD001 54 14.0 61.1
AI→ EXE 239 0.4 18.0
AI→ EXE + RAD001 484 9.5 33.4
oxifen, FUL: fulvestrant, SERM: selective estrogen receptor modulator.
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unresponsive tumors.
The three preceding options all target ER signaling,
but some breast cancers become resistant to such ther-
apies. Several molecular mechanisms have been pro-
posed to be responsible for endocrine resistance. Loss of
ER expression, altered activity of ER coregulators, de-
regulation of apoptosis and cell cycle signaling, and
hyperactive receptor tyrosine kinase (RTK) and stress/
cell kinase pathways can collectively orchestrate the de-
velopment and sustenance of pharmacologic resistance
to endocrine therapy [15].
Thus, a fourth category of therapies involves membrane-
bound receptors for growth factors, such as the human
EGF receptor (HER) family or insulin like growth factor re-
ceptor, which are active even in estrogen-dependent tu-
mors. Treatment that combines endocrine therapy with
inhibition of these growth factor receptors, or molecularly
targeted treatment to inhibit their signal transmission, can
be effective. mTOR (mammalian target of rapamycin) is a
serine/threonine kinase in the downstream Akt pathway,
which strongly affects cell survival and proliferation.
Recently, the phase III, Borelo2 trial, found that com-
bination treatment with everolimus, an mTOR inhibitor,
and exemestane had a statistically significant beneficial
effect compared with exemestane alone in ORR (7.4% vs.
0.4%, respectively), and PFS (10.6 months vs. 4.1 months,
respectively) [16]. Furthermore, another randomized
phase II trial, the TAMRAD trial, comparing the com-
bination everolimus and tamoxifen with tamoxifen alone
showed a better CBR (61% vs. 42%) and longer TTP
(8.6 months vs. 4.5 months) for the combination [17].
Interestingly, the efficacy of their control arms was simi-
lar to our results. ORR of EXE in Bolero 2 trial was 0.4%
and 2.2% in ours, and CBR of TAM was 42% in the
TAM-RAD trial and 41.3% in ours (Table 4). This fur-
ther increases our confidence in our results.
Conclusions
In summary, our study suggests that TOR120 should be
regarded favorably as a subsequent endocrine therapy
for recurrent breast cancer with non-steroidal AI failure,
though with due attention to adverse symptoms, such as
nausea and general fatigue. When choosing a subsequent
endocrine therapy, it is important to select one that has
endocrine therapy which has different mechanisms from
prior therapy.
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